Older Americans are quitting GLP-1 weight-loss drugs for 4 key reasons

A JAMA study of >125,000 overweight or obese patients found high discontinuation of GLP-1 therapies within a year (≈47% with type 2 diabetes, 65% without), with older adults particularly affected given ~40% obesity prevalence. Key drivers of non-adherence are cost and coverage losses (examples of copays jumping from $25 to >$1,000/month), tolerability (GI side effects, dehydration) and clinically meaningful muscle loss in seniors, which can negate cardiometabolic benefits and raise safety concerns. These trends imply downside risk to GLP-1 revenue durability and uptake forecasts, heightened payer and access scrutiny, and potential need for manufacturers to adjust pricing, delivery and patient-management strategies (e.g., Lilly’s announced price cut for tirzepatide vials).

Analysis

Market structure: Large-cap GLP-1 originators (NVO, LLY) retain pricing power but face a lower-than-advertised effective market because real-world adherence is weak — JAMA: ~47% (T2D) and ~65% (non‑T2D) stop within a year — which compresses lifetime revenue per patient by an order of magnitude versus chronic-use models. Payer formulary actions and out‑of‑pocket shocks will shift share toward lower‑priced competitors, compounding pharmacies and off‑label cash markets, while insurers/PBMs can extract margin by restricting coverage.

Risk assessment: Key tails are (1) class safety/regulatory action (label warnings on muscle loss/dehydration) triggering 20–40% demand shock, (2) broad payer coverage removals (Medicare/MA or 10 largest PBMs) within 30–90 days, and (3) supply shortages driving short‑term price spikes but long‑term access erosion. Immediate volatility will cluster around payer announcements and quarterly prints (next 30–90 days); structural impacts play out over 6–24 months as adherence and chronicity data accumulate.

Trade implications: Favor defensive, option‑structured long exposure to NVO/LLY to capture continued secular demand while capping downside (6–12 month call spreads ATM vs 10–15% OTM). Short lower‑quality consumer/clinic names (WW, small specialist chains) that rely on first‑time, cash customers who churn quickly. Hedge portfolio tail risk with low‑cost put spreads keyed to regulatory/payer headlines in the 3‑month window.

Contrarian angles: Consensus treats high discontinuation as permanent TAM loss; history (statins, SGLT2) shows adherence initially low then chronicized with better dosing, combos and reimbursement—price cuts (LLY) can expand volume and increase lifetime value if payers accept narrower margins. Mispricing exists in small‑cap consumer exposures that assume sustained recurring revenue; big pharma multiples already price in chronic adoption, so use option structures rather than outright buys.

Key Decisions for Investors

• Establish a 2–3% portfolio long in NVO via a 6–12 month call spread (buy ATM call, sell 10–15% OTM call) to capture durable GLP‑1 demand while limiting downside; add up to +1.5% if sequential global GLP‑1 volume growth >12% q/q or net price/mix declines <5% on next quarterly report.
• Initiate a 1.5–2% long position in LLY (stock or 9‑month LEAP call) to play Zepbound access moves and device/price initiatives; liquidate if company announces an incremental price cut >10% or reports net new patient additions <5% q/q for two consecutive quarters.
• Implement a pair trade: long NVO (2%) / short WW (WW) (1.5%) to capture relative resilience of large pharma versus cash‑dependent consumer weight‑loss operators; unwind if the pair diverges by <3% over a 3‑month window or if WW reports improving multi‑month retention >10%.
• Buy 3‑month put spreads (cost‑limited hedge) equal to 0.5–1% portfolio notional keyed to regulatory/payer risk (targeting out‑of‑the‑money strikes ~10% below current) to protect against a sudden class‑wide safety or coverage removal; monitor CMS/PBM formulary decisions and reduce NVO/LLY exposure by 50% within 48 hours if a top‑5 payer delists GLP‑1s for obesity.